<DOC>
	<DOCNO>NCT02365935</DOCNO>
	<brief_summary>The investigator primary outcome evaluate effectiveness term Overall Survival ( OS ) disease free interval ( DFI ) two different platinum-based chemotherapic regimen ( 3 6 cycle ) treatment Locally Advanced Cervical Cancer ( LACC ) ( IB2-IIB ) previously treat Neoadjuvant Chemotherapy Plus Radical Surgery ( NACT+RS ) . The secondary outcome evaluate compare safety , term toxicity profile , two treatment option .</brief_summary>
	<brief_title>4 Versus 6 Courses Adjuvant Chemotherapy LACC Patients Previously Treated With NACT Plus Radical Surgery</brief_title>
	<detailed_description>Between February 2007 January 2013 , patient diagnosis LAAC refer Division Gynecologic Oncology Campus Bio-Medico University Rome , eligible protocol . The institutional internal review board approve study . Inclusion criterion : I ) Patients squamous cell , adenosquamous adenocarcinoma cervix ; II ) Stage IB2-IIB accord International Federation Gynecology Obstetrics ( FIGO ) ; III ) age 18 75 year ; IV ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0-2 ; V ) normal cardiac respiratory function ; VI ) absence secondary malignancy ; VII ) previous surgical , chemotherapic and/or radiotherapic treatment secondary malignancy VIII ) inform consent obtain patient.Exclusion criterion include : I ) histological confirmation papillary serous , mucinous , clear cell , squamous cell , mixed undifferentiated carcinoma uterus ; II ) abnormal hepatic function ( transaminases &gt; 2.5 x upper limit , serum bilirubin &gt; 1,5 x upper limit ) ; III ) abnormal renal function ( creatinine clearance &lt; 60 mL/min and/or serum creatinine &gt; 2.0 mg/100 mL ) function ; IV ) abnormal bone marrow function ( absolute neutrophil count &lt; 1,5 x 109/L platelet count &lt; 100 x 109/L hemoglobin &lt; 9 g/dL ; V ) severe uncontrolled infection , systemic disease mental illness ; VI ) pregnant woman . Clinical staging perform accord NCCN criterion , include pelvic examination , cervical biopsy , abdomen-pelvis Computed Tomography , chest X-ray ; examination anesthesia , cystoscopy and/or proctoscopy clinically indicate ( National Comprehensive Cancer Network , Clinical Practicw Guidelines Oncology . Cervical Cancer , Version 2.2015 ) All patient meet inclusion exclusion criterion enrol receive 3 cycle neoadjuvant chemotherapy ( NACT ) every three week accord scheme Cisplatin 100 mg/mq Paclitaxel 175 mg/mq . Complete response define complete disappearance clinically detect able disease , determine 2 observation less 4 week apart . Partial response record â‰¥50 % reduction total tumor size , determine 2 observation less 4 week apart . No response stable disease define &lt; 50 % decrease tumor size &lt; 25 % increase size one measurable lesion . Progressive disease define &gt; 25 % increase size appearance new lesion . After NACT patient stable progressive disease exclude protocol , others underwent bilateral systematic pelvic lymph node dissection , classical radical hysterectomy bilateral salpingo-oophorectomy . Aortic lymphadenectomy , level inferior mesenteric artery , reserve patient pelvic node disease intraoperative examination find bulky aortic node time surgery . In case positive aortic node , hysterectomy perform , patient exclude protocol refer radiation oncologist . Similarly patient present positive surgical margin close vaginal margin ( &lt; 0.5 mm ) final pathology , exclude study refer radiotherapist . After surgery randomly allocate undergo 4 6 cycle chemotherapy use predetermine computer-generated randomisation code . In Group A , patient receive 4 cycle adjuvant chemotherapy every three week accord scheme Cisplatin 100 mg/mq Paclitaxel 175 mg/mq.In Group B , patient receive instead 6 cycle adjuvant chemotherapy every three week accord chemotherapic regimen . Adjuvant chemotherapy start within 28 day surgery . Follow-up procedure include physical examination vaginal cytology every 3 month 2 year , every 6 month 5th year accord NCCN 2015 total body CT . Therefore patient suspicion relapse , total body CT anticipate . To assess sample size , agreement investigator experience , investigator estimate 20 % reduction toxicity profile patient receive 4 cycle adjuvant chemotherapy compare receive 6 cycle ( 11 ; 19 ) . Considering power 80 % , detect statistically significant difference ( alpha = 0.5 ; P = 0.05 Long Rank Test ) , 100 patient necessary treatment arm . OS DFS curve estimate use Kaplan-Meier method difference compare use log-rank test . The comparison variables two group evaluate use Mann-Whitney test , chi-square test , Fisher test . Statistical significance set p &lt; 0.05 . DFS , OS recurrence rate analyze patient complete study protocol ; toxicity profile two treatment group , however , statistically analyzed consider patient randomize enrolled study protocol treatment NACT + RS .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>patient squamous cell , adenosquamous adenocarcinoma cervix Stage IB2IIB accord Inyernational Federation Gynecology Obstetrics ( FIGO ) age 18 75 year Eastern Cooperative Oncology Group ( ECOG ) performance status 02 normal cardiac respiratory function absence secondary malignancy previous surgical , chemotherapic and/or radiotherapic treatment secondary malignancy inform consent obtain patient . histological confirmation papillary serous , mucinous , clear cell , squamous cell , mixed undifferentiated carcinoma uterus abnormal hepatic function ( transaminases &gt; 2.5 x upper limit , serum bilirubin &gt; 1,5 x upper limit ) abnormal renal function ( creatinine clearance &lt; 60 mL/min and/or serum creatinine &gt; 2.0 mg/100 mL ) function abnormal bone marrow function ( absolute neutrophil count &lt; 1,5 x 109/L platelet count &lt; 100 x 109/L hemoglobin &lt; 9 g/dL severe uncontrolled infection , systemic disease mental illness ; pregnant woman . Clinical staging perform accord NCCN criterion , include pelvic examination , cervical biopsy , abdomenpelvis Computed Tomography , chest Xray ; examination anesthesia , cystoscopy and/or proctoscopy clinically indicate ( National Comprehensive Cancer Network , Clinical Practicw Guidelines Oncology . Cervical Cancer , Version 2.2015 )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>adjuvant chemotherapy</keyword>
</DOC>